Clinical trials: Are data managers ready for AI in EDC?
AI in clinical trials has the potential to offer faster insights, greater efficiency, and improved data quality. Nowhere is this…
Partner Content
-
-
Nine ways to ensure a reliable technology transfer
While these transfers are a normal part of business, navigating them requires a strategic approach to ensure smooth and efficient…
-
How the AI shift is happening now in data management
The newest generation of AI-driven tools is beginning to reshape how clinical databases are built, governed, and maintained. This is…
-
Extracellular vesicles: The next frontier in regenerative medicine and drug delivery?
Extracellular vesicles (EVs) are tiny, membrane-bound particles released by every cell type studied to date. Though small, they carry a…
-
Dermatology Trials by the Numbers: Key Trends and Benchmarks for 2026
Dermatology - spanning chronic inflammatory disease, infection, wound healing, pigment disorders, hair loss and rare genetic conditions - is nothing…
-
CinnaGen Enters EU Market with EMA Approval for Zandoriah®
CinnaGen today announced that the European Medicines Agency (EMA) has adopted a positive opinion recommending the approval of Zandoriah® (teriparatide),…
-
Enhancing clinical trials in obesity by integrating clinical outcome assessments (COAs) and digital health technologies (DHTs)
As obesity reaches epidemic proportions worldwide, clinical trial teams face mounting pressure to demonstrate meaningful health benefits beyond weight loss…
-
OEB 6: The new standard in high-potent molecule manufacturing?
In recent years, the pharmaceutical industry has seen a significant increase in the development of highly potent active pharmaceutical ingredients…
-
RWD and RWE are rewriting how we design and run trials
Traditional randomized controlled trials (RCTs) have long been the gold standard for testing new therapies, but they are increasingly strained…
-
A New Strategic Blueprint: Designing Smarter Early Phase Trials in Oncology
Cancer drugs form one of the most dynamic segments of pharmaceuticals, powered by rising incidence, ageing populations, deeper cancer biology,…